Home
News Channels
Financial
News Channels
Financial
|
World Pharma News RSS Channel
Subscribe to World Pharma News by Email
Follow us on: |
Research & Development
Conferences & Events
- Safety Biomarkers in Drug Development Conference to be held in Bratislava, Slovak Republic
- 4th Annual Clinical Site Partnerships in Central & Eastern Europe, to be held in Budapest, Hungary
- Physicians Go Digital Across the Globe - Webinar May 19
- Emerging Superpowers of Clinical Research - Russia, India, China
Financial News Channel
Sponsored Ads |
Pharmaceutical CompaniesA | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | ZSponsored AdsPharmaceutical RSS NewsAbbott | Amgen | AstraZeneca | Boehringer Ingelheim | Bristol-Myers Squibb | Eli Lilly | GlaxoSmithKline | Janssen-Cilag | Johnson & Johnson | Novartis | Novo Nordisk | Pfizer | Roche | Shire | Takeda | ... European Commission - Pharmaceuticals US Food and Drug Administration Sponsored Ads
PharmaNews.eu, an advanced web based news engine, addressed to the European pharmaceutical domain, has been launched. The project was developed to directly connect, promote and disseminate the European pharmaceutical news...For further information and advanced RSS channels, please visit http://www.pharmanews.eu PharmaNews.eu / Latest News |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial
Product
- IRESSA (Gefitinib) Receives Marketing Authorisation in Europe
- AstraZeneca Development Partner, Pozen, Inc., Submits New Drug Application for PN400
- Lundbeck receives FDA Complete Response Letter on Serdolect® for the treatment of schizophrenia
- New biological therapy Ilaris® approved in US
- Nycomed receives Marketing Authorization for Pantoprazole 20mg OTC from European Commission
Clinical Trials
- Lu AA24530 shows positive results in major depressive disorder phase II study
- Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
- Pfizer Discontinues Phase 3 Trial of Sutent® in Metastatic Colorectal Cancer
- Sutent Significantly Improved Progression-Free Survival
- Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
Corporate
- Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecules from Pfizer
- Bayer files patent infringement lawsuit against Teva
- Bayer Schering Pharma Extends Research Portfolio in the Field of Cancer-Related Targets
- Novo Nordisk reaches settlement with the Danish authorities regarding Oil-for-Food activities
- GSK and Chroma Therapeutics form alliance to develop novel macrophage-targeted drugs
Nycomed reports a solid start to 2009, with total net turnover increasing by 1.2% to €839.9 million, despite adverse impact from currency movements. Excluding the effects of currency, the increase was 3.8%, underlining the solid performance of the main product Pantoprazole and other key products. On a regional basis, most Nycomed markets performed in line with or above expectations.
Novartis has signed a definitive agreement to acquire the specialty generic injectables business of EBEWE Pharma, providing Sandoz - the Group's generic pharmaceuticals division - an opportunity to create a strong global platform for future growth while improving access for patients worldwide to many generic oncology medicines.
GlaxoSmithKline plc (GSK) has entered into an agreement to divest full commercial rights to Wellbutrin XL® in the United States to Biovail International Laboratories SRL, a subsidiary of Biovail Corporation (NYSE, TSX: BVF), for $510 million (£340 million). The agreement is subject to Hart-Scott-Rodino regulatory clearance in the United States.
Pfizer Inc (NYSE: PFE) has reported financial results for first-quarter 2009. Revenues were $10.9 billion, a decrease of 8% compared with the year-ago quarter. Foreign exchange unfavorably impacted revenues by approximately $640 million or 5%. For first-quarter 2009, U.S. revenues were $5.0 billion, a decrease of 10% compared with the year-ago quarter.
All in all, the Merck Group performed solidly during the first quarter of 2009. However, Merck is not an island. The recession is affecting the company's results, mainly in the Chemicals business sector. In addition, this year's first quarter is compared to a very strong first quarter in 2008.
Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.08 for the first quarter of 2009, a decrease of 4 percent compared to $1.12 for the first quarter of 2008. Adjusted net income decreased 8 percent to $1,120 million in the first quarter of 2009 compared to $1,218 million in the first quarter of 2008.
The Roche Group recorded total sales of 11.6 billion Swiss francs in the first quarter of 2009, an increase of 8% in local currencies (7% in Swiss francs; -1% in US dollars)1 compared with the year-earlier period. Growth was driven mainly by continued strong sales of key products in the Group's oncology, virology, ophthalmology and inflammation portfolios, and of Roche Diagnostics' immunoassay systems.
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has signed a binding agreement for the acquisition of BiPar Sciences, Inc., ("BiPar") a privately held US biopharmaceutical company, developing novel tumorselective approaches for the treatment of different types of cancers.
Abbott has announced financial results for the first quarter ended March 31, 2009. Diluted earnings per share, excluding specified items, were $0.73, reflecting 15.9 percent growth, and $0.03 above the mid-point of Abbott's previous first-quarter guidance range. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.92, up 53.3 percent.
